AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases-Reference-Cited by-同舟云学术

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

Published:2016-12-07 Issue:368 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Yang Zhenfan¹,Guo Qiuli¹,Wang Yingchun¹,Chen Kan¹,Zhang Lin¹,Cheng Ziqiang¹,Xu Yanping¹,Yin Xiaolu¹,Bai Yu¹,Rabbie Sarit²,Kim Dong-Wan³,Ahn Myung-Ju⁴,Yang James Chih-Hsin⁵,Zhang Xiaolin¹

Affiliation:

1. Asia Innovative Medicines, AstraZeneca, Shanghai 201203, China.

2. Early Clinical Development, AstraZeneca, Cambridge, Hertz SG8 6EE, U.K.

3. Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.

4. Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Irwon-ro, Gangnam-gu, Seoul 135-710, South Korea.

5. Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, 7, Chung-Shan South Road, Taipei 10002, Taiwan, ROC.

Abstract

AZD3759 can penetrate the blood-brain barrier to treat EGFR mutant non–small-cell lung cancer with CNS metastases.

Funder

AstraZeneca

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference41 articles.

1. Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

2. Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation

3. Leptomeningeal carcinomatosis: Prognostic value of clinical, cerebrospinal fluid, and neuroimaging features

4. EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: A pooled analysis of published data;Fan Y.;Onco. Targets Ther.,2014

5. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis;Translational Oncology;2024-01

2. Discovery of a Hydroxylamine-Based Brain-Penetrant EGFR Inhibitor for Metastatic Non-Small-Cell Lung Cancer;Journal of Medicinal Chemistry;2023-11-07

3. Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial;eClinicalMedicine;2023-10

4. Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer;Nature Reviews Clinical Oncology;2023-08-17

5. Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases;Translational Oncology;2023-05